Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Florida Health Daily.
April 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | |
| 7 | 8 | 9 | 10 | 11 | 12 | 13 |
| 14 | 15 | 16 | 17 | 18 | 19 | 20 |
| 21 | 22 | 23 | 24 | 25 | 26 | 27 |
| 28 | 29 | 30 |
May 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | |||
| 5 | 6 | 7 | 8 | 9 | 10 | 11 |
| 12 | 13 | 14 | 15 | 16 | 17 | 18 |
| 19 | 20 | 21 | 22 | 23 | 24 | 25 |
| 26 | 27 | 28 | 29 | 30 | 31 |
June 2025
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
| 1 | ||||||
| 2 | 3 | 4 | 5 | 6 | 7 | 8 |
| 9 | 10 | 11 | 12 | 13 | 14 | 15 |
| 16 | 17 | 18 | 19 | 20 | 21 | 22 |
| 23 | 24 | 25 | 26 | 27 | 28 | 29 |
| 30 |
Press releases published on March 21, 2025
GlowSpring Health Uses Comprehensive 5-Point Model to Address Fatigue Naturally
EIN Presswire
·
March 21, 2025
GlowSpring Health’s 5-Point Model targets fatigue at its root with a holistic, natural approach to restore energy, balance hormones, and boost wellness. LONGWOOD, FL, UNITED STATES, March 21, 2025 /EINPresswire.com/ -- GlowSpring Health, a trusted name …
Atea Pharmaceuticals Issues Statement Regarding Director Nominations
GlobeNewswire
·
March 21, 2025
BOSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (Atea or Company) a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today …
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
GlobeNewswire
·
March 21, 2025
SAN CARLOS, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte (“TIL …
Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
GlobeNewswire
·
March 21, 2025
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and …
Restore Value Slate Led by Mina Sooch Files Preliminary Proxy Materials for the Election of Six Highly Qualified Directors at the 2025 Annual Meeting of Opus Genetics
GlobeNewswire
·
March 21, 2025
Believes that Current Board’s Strategic, Management and Capital Allocation Failures have Resulted in Stockholder Value Destruction Highlights Serious Concerns with the Opus Merger and the Company’s Underperformance Preliminary Proxy Materials Present an …
Autonomix Medical, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 21, 2025
THE WOODLANDS, TX, March 21, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company focused on advancing innovative technologies to revolutionize how diseases involving the nervous system …
Immuneering Corporation Announces Grant of Inducement Award
GlobeNewswire
·
March 21, 2025
CAMBRIDGE, Mass., March 21, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company seeking to develop and commercialize more effective and better tolerated therapies for cancer patients, previously announced on …
Baylor Genetics Presents New Data on Genetic and Functional Testing to Diagnose Mitochondrial Disorders at 2025 ACMG Annual Clinical Genetics Meeting
GlobeNewswire
·
March 21, 2025
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Baylor Genetics, a clinical diagnostic laboratory celebrating a decade at the forefront of genetic testing, today shared research on the value of both genetic and functional testing in diagnosing mitochondrial …
I-Mab Announces Receipt Of Nasdaq Deficiency Notice Regarding Minimum Bid Price Requirement
GlobeNewswire
·
March 21, 2025
ROCKVILLE, Md., March 21, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (“I-Mab” or the “Company”), announced today that on March 19, 2025 it received a written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC …
Eagle Pharmaceuticals Announces Amendment to Limited Duration Stockholder Rights Plan
GlobeNewswire
·
March 21, 2025
WOODCLIFF LAKE, N.J., March 21, 2025 (GLOBE NEWSWIRE) -- Eagle Pharmaceuticals, Inc. (OTCMKTS: EGRX) (the “Company” or “Eagle”) today announced that its Board of Directors (the “Board”) has approved an amendment to its previously disclosed limited duration …
Entourage Health Corp. Announces Shareholder Approval of Going-Private Transaction
GlobeNewswire
·
March 21, 2025
TORONTO, March 21, 2025 (GLOBE NEWSWIRE) -- Entourage Health Corp. (TSX-V: ENTG) (OTCQX: ETRGF) (FSE: 4WE) (the “Company” or “Entourage”) is pleased to announce that the shareholders of the Company (the “Shareholders”) have approved the proposed plan of …
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
·
March 21, 2025
PALO ALTO, Calif., March 21, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced that on March 19, 2025, the compensation …
Prime Biome Complaints & Consumer Reports (URGENT) Buyers Reveal Unexpected Insights About Side Effects & Effectiveness
GlobeNewswire
·
March 21, 2025
Boston, March 21, 2025 (GLOBE NEWSWIRE) -- Boston — March 21, 2025 (GLOBE NEWSWIRE) – Gut health and skin care have always been treated as separate issues, with people relying on skincare products for clearer skin and digestive aids for bloating or …
Impact Biomedical Inc. Announcement Stock Activity/Pricing
GlobeNewswire
·
March 21, 2025
HOUSTON, March 21, 2025 (GLOBE NEWSWIRE) -- Impact BioMedical Inc. (NYSE American: IBO), a pioneering biotechnology company dedicated to discovering, developing, and patenting innovative healthcare solutions, today announced that there has been no material …
Yaqrit 获得 NIHR 拨款，用以对肝衰竭患者进行肝脏支持装置 DIALIVE 的关键试验
GlobeNewswire
·
March 21, 2025
由 UCL、Royal Free、Kings College 和 Queen Elizabeth Birmingham 牵头，在英国 13 个试验中心开展重症监护肝脏支持系统评估试验 快速评估将于 10 天和 28 天内完成共同主要终点的测量；数据揭盲时间定为 2027 年第一季度 旨在解决危及生命的疾病，改善患者生存期 伦敦, March 22, 2025 (GLOBE NEWSWIRE) -- Yaqrit 是一家开发晚期肝病救生疗法的后期临床公司，该公司今天宣布获得一笔 220 万英镑（约合 285 …
STRATA Skin Sciences to Report Fourth Quarter and Year End 2024 Financial Results on March 27, 2025 and Provide Corporate Update
GlobeNewswire
·
March 21, 2025
HORSHAM, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of …
Better Choice Company Shareholders Overwhelmingly Approve Acquisition of SRx Health Solutions and Related Proposals
GlobeNewswire
·
March 21, 2025
TAMPA, Fla., March 21, 2025 (GLOBE NEWSWIRE) -- Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, is pleased to announce that the Company’s shareholders approved the following proposals …
Opus Genetics Announces Presentation on Phentolamine Ophthalmic Solution 0.75% in Dim Light Disturbances at World Cornea Congress IX
GlobeNewswire
·
March 21, 2025
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) and therapies for other …
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
GlobeNewswire
·
March 21, 2025
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to …
Opus Genetics Announces Pricing of Public Offering and Concurrent Private Placement with Proceeds of Over $20 Million
GlobeNewswire
·
March 21, 2025
RESEARCH TRIANGLE PARK, N.C., March 21, 2025 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (“Opus” or the “Company”) (Nasdaq: IRD), a clinical-stage ophthalmic biotechnology company developing gene therapies for the treatment of inherited retinal diseases (IRDs) …